-
2019
- Medicilon Inc. – Announcement of an IPO
on Sci-Tech Innovation Board in China
- (stock code : 688202.SH)
- Fifteenth Anniversary Celebration Series
- Passed the Review of GLP & AAALAC
-
2018
- Nanhui R&D Center Officially Operate
- IND approved in Sweden
-
2017
- Medicilon established the preclinical cardiac safety
assessment study platform
- Established the clinical BE biological analysis platform
- Established an inhalation and ophthalmic administration
evaluation platform
- Established the registration and declaration service platform
- Expand the Tumor Center
- The introduction of new high-throughput
Biacore experimental instrument
- The introduction of new
multiple LC-MS / MS mass spectrometers
-
2016
- Medicilon was awarded as “Shanghai Academicians and Experts Workstation Qualified Unit”
- Medicilon completed the construction of preparation center and microbial laboratory
- Medicilon completed the construction of preparation center and GMP pilot plant
- Established the tumor immunology service platform
- Established the biotechnology drug and bioanalysis service platform
- Established the ADC (Antibody Drug Conjugate) preclinical service platform
- Establish a "Generic Drug Quality Consistency Assessment Service Platform"
- The introduction of the new mass spectrometer, Triple Quad 6500
- The introduction of the new IVIS Lumina III Imaging System
-
2015
- Expansion of the New Laboratory Area with 10,000 square meters
- Medicilon held first Congress of science and technology Association
-
2014
-Tenth Anniversary Celebration Series
-Approved the Establishment of Academicians and Experts Workstations
-Expansion of the New Laboratory Area with 10,000 square meters
-Expand Isotope Biomarker Services
-Passed the Review of CFDA GLP
-
2013
-Successfully introduce new foreign drugs to domestic
pharmaceutical companies.
-Establishment of new three party collaboration model:
Foreign Enterprise – Medicilon – Domestic
Pharmaceutical Company.
-Chinese government officially approve Shanghai
Medicilon Inc. become the holding company of
MPI Preclinical Research (Shanghai) LLC.
-
2012
- Participate the filming of “DaDaoTongXing” as
the representative of Shanghai high-tech enterprises.
- Provide the complete application for both CFDA and
FDA IND filing.
- Three party collaboration to promote the drug
development process.
- Undertake the “Twelve Five Year Project” on
creating new drug task.
- GLP is successfully reviewed by both FDA and CFDA.
-
2011
- China’s SFDA officially approved
Medicilon’s GLP Certification.
- Medicilon recognized as a “Cultivated
Little Giant Enterprise” in Shanghai’s high
technology industry.
-
2010
- Fortune Capital signed investment
agreement with Medicilon aimed for
IPO in China.
- Medicilon is recognized as one of the
top seven integrated services CRO in
China in Citi Investment’s report.
- Medicilon "Shanghai isotope Drug
Metabolism professional and technical
services platform", selected the first
batch of ”Shanghai professional and
technical service platform”.
-
2009
- Medicilon acquires international AAALAC Accreditation.
- Medicilon preclinical research facilities compliance
with US GLP standard.
- “Protein-crystallography-based Drug Discovery
and Screen Platform” of Medicilon was listed in
Shanghai R&D Public.
- “NHP Experimental Service Platform” of
Medicilon/MPI was listed in Shanghai R&D Public
Service Platforms.
- Medicilon established CMC platform.
-
2008
- Animal facility in Medicilon approved by Shanghai
Animal Committee, was issued the License of
Laboratory Animal (Rat, Mouse, Dog and Monkey).
- The joint venture company, Medicilon Preclinical
Research, registered in Shanghai, begins to provide
preclinical GLP services.
- Laboratories expanded to 20,000 square meters
in the Chuansha campus which include the large
animal facility (40 animal rooms) in Shanghai.
-
2007
- Joint Venture agreement between Shanghai
Medicilon Inc. and MPI Research signed.
- Commenced non-GLP preclinical research and
projects.
-
2006
Enterprise by Shanghai Science Commission.
-
2005
- Trademark “美迪西”(Medicilon Inc.) approved by Chinese
government.
- Animal facilities were issued their respective licenses
(Rat, Mouse, Rabbit, Dog and Non-human primates).
- Established the first chemical synthesis FTE team.
-
2004
- Medicilon registered in Shanghai,
Laboratory construction in
Zhangjiang Hi-tech Park.
- Initially provided Chemistry and
Bioanalysis Services .
- First LC/MC/MC was imported
for pharmacokinetics services.
